DRTS Alpha Tau Medical Ltd. - Class A

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers. The company was founded in 2015 and is headquartered in Jerusalem, Israel.

$11.62  -0.26 (-2.19%)
As of 06/28/2022 15:52:34 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  03/08/2022
Outstanding shares:  68,480,916
Average volume:  201,178
Market cap:   $818,346,946
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   -23.53
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%